The Braden Scale is a standardized tool to assess pressure ulcer risk that is reported for all hospitalized patients in the United States per requirements of the Center for Medicare and Medicaid Services. Previous data have shown the Braden Scale can predict both frailty and mortality risk in patients with decompensated cirrhosis. Our aim was to evaluate the association of the Braden Scale score with short-term outcomes after liver transplantation (LT). We performed a retrospective cohort study of deceased donor LT recipients at 2 centers and categorized them according to the Braden Scale at hospital admission as low (>18), moderate (16-18), or high risk (<16) for pressure ulcer. We created logistic and Poisson multiple regression models to evaluate the association of Braden Scale category with in-hospital and 90-day mortality, length of stay (LOS), nonambulatory status at discharge, and discharge to a rehabilitation facility. Of 341 patients studied, 213 (62.5%) were low risk, 59 (17.3%) were moderate risk, and 69 (20.2%) were high risk. Moderate-and high-risk patients had a greater likelihood for prolonged LOS, nonambulatory status, and discharge to a rehabilitation facility, as compared with low-risk patients. Highrisk patients additionally had increased risk for in-hospital and 90-day mortality after LT. Multiple regression modeling demonstrated that high-risk Braden Scale score was associated with prolonged LOS (IRR, 1.56; 95% confidence interval [CI], 1.47-1.65), nonambulatory status at discharge (odds ratio [OR], 4.15; 95% CI, 1.77-9.71), and discharge to a rehabilitation facility (OR, 5.51; 95% CI,). In conclusion, the Braden Scale, which is currently assessed in all hospitalized patients in the United States, independently predicted early disability-related outcomes and greater LOS after LT.
The concept of frailty, or a "patient's vulnerability to stress and decreased physiologic reserve" was initially developed as a prognostic indicator in the geriatric population.
(1) Among patients with end-stage liver disease, physiologic reserve is an important prognostic indicator for wait-list mortality. Several assessments of frailty have been validated in the outpatient setting regarding wait-list mortality including the Fried Frailty Index (2) and the 6-minute walk test. (3) However, the relationship between these tools and outcomes after liver transplantation (LT) is uncertain because these measures have not been validated in hospitalized patients and are difficult to assess in functionally impaired patients, such as those with severe hepatic encephalopathy, who are nonambulatory, or are receiving renal replacement therapy or mechanical ventilation.
The Braden Scale is a metric of pressure ulcer risk that is required by the Center for Medicare and Medicaid Services to be assessed in all hospitalized patients in the United States. (4) In the study from Tapper et al. of hospitalized patients with cirrhosis, the Braden Scale independently predicted 90-day mortality after discharge, length of stay (LOS) in the hospital, and discharge to a rehabilitation facility. (5) Therefore, this tool appears to be a novel marker of physiologic reserve in hospitalized patients with end-stage liver disease. However, functional impairment as measured by the Braden Scale has not been previously evaluated as a predictor of clinical outcomes after LT.
The aim of our study was to evaluate the association between Braden Scale score and early post-LT outcomes including mortality, LOS, hospital readmission, nonambulatory discharge status, and discharge to a rehabilitation facility. On the basis of previous research evaluating outcomes in end-stage liver disease, (5) we hypothesized that patients at high risk for pressure ulcers, as defined by a Braden Scale score of <16, would have increased shortterm post-LT mortality, LOS, nonambulatory status at discharge, and discharge to a rehabilitation facility.
Patients and Methods

STUDY POPULATION
We performed a retrospective cohort study of patients receiving deceased donor LT at Cedars-Sinai Medical Center (CSMC) from January 1, 2011 to December 31, 2014 and Oregon Health and Science University (OHSU) from January 1, 2011 to May 31, 2016. We excluded patients under 18 years of age, multiorgan transplant recipients, and patients with missing data for Braden Scale score or study outcomes. For recipients of retransplantation, we evaluated the variables and outcomes associated with the most recent LT event.
The primary exposure was the Braden Scale score measured at the time of hospital admission (Supporting Fig.  1 ). The Braden Scale includes the sum of individual scores in 6 domains: skin sensory perception, moisture, activity, mobility, nutrition, and friction (ability to hold a comfortable position in a chair and bed). A total score of 23 indicates no risk of skin breakdown, whereas a score of <16 indicates a recommendation for nutrition and/or physical therapy consultation to forestall a high risk for nosocomial pressure ulcers. We categorized patients as low risk (score-> 18), moderate risk (16) (17) (18) , and high risk (<16) for pressure ulcer, a stratification schema used in previous studies of patients with (5) and without cirrhosis. (6) We also evaluated other covariates, including demographics, etiology of liver disease, history of diabetes, body mass index (BMI), biochemical Model for EndStage Liver Disease-sodium (MELD-Na) score, receipt of a Model for End-Stage Liver Disease (MELD) exception, history of transjugular intrahepatic portosystemic shunt (TIPS), history of portal vein thrombosis (PVT), presence of hepatocellular carcinoma (HCC), laboratory data, mechanical ventilation at time of LT, hemodialysis at time of LT, and duration of the LT surgery.
The study outcomes were in-hospital post-LT mortality, 90-day post-LT mortality, nonambulatory status at hospital discharge, 30-day hospital readmission, LOS, and discharge disposition to a rehabilitation facility. Nonambulatory status was determined by review of physical therapy records at hospital discharge. Patients were deemed to be ambulatory if they could walk independently, with assistance, or with a front-wheeled walker, whereas patients who were wheelchair-or bedbound were considered to be nonambulatory.
Institutional review boards at both sites approved the study. We adhered to Strengthening the Reporting of Observational Studies in Epidemiology recommendations for observation cohort studies for the study design and analysis. 
SAMPLE SIZE CALCULATION AND STATISTICAL ANALYSIS
We estimated that a sample size of 305 patients would be needed to achieve an 80% power to detect a 2-sided P < 0.05 difference between Braden Scale categories using the chi-square method for independent proportions, estimating the allocation ratios (20% Braden Scale score < 16; 5% Braden Scale score 16-18; and 70% Braden Scale score > 18) and effect sizes from a previously published study evaluating frailty in a similar cohort of patients with decompensated cirrhosis. (5) We compared continuous variables using Student t test and categorical variables using chi-square or Fisher's exact testing. We used univariate logistic regression to evaluate the association between Braden Scale category and in-hospital and 90-day mortality, and both univariate and multivariate logistic regression to evaluate discharge to a rehabilitation facility, nonambulatory status at discharge, and 30-day readmission, and Poisson regression to evaluate LOS. We selected covariates for inclusion in the multivariate models using manual backward selection, with elimination of variables that were nonsignificant (P > 0.1) in univariate analysis. Goodness of fit was tested with the Hosmer-Lemeshow method. To evaluate for heterogeneity by study site, we tested for interactions between Braden Scale category and site for each outcome. All statistical analyses were performed with STATA software, version 14 (Statacorp, College Station, TX). A 2-sided P value < 0.05 was considered to be significant.
Results
Of 414 total patients undergoing deceased donor LT from January 1, 2011 through May 31, 2016 at the 2 sites, 197 patients were from CSMC and 217 patients were from OHSU ( Fig. 1) . Similar proportions of patients were excluded based on the study criteria (14.2% CSMC versus 20.7% OHSU; P 5 0.08), resulting in 341 patients in the final analytic cohort.
Comparing Braden Scale categories, 213 (62.5%) patients were deemed low risk, 59 (17.3%) were moderate risk, and 69 (20.2%) were high risk ( Table 1 ). The groups did not differ by age, sex, race/ethnicity, BMI, history of PVT, prior TIPS, retransplantation, or serum albumin levels. High-risk patients had more severe liver-related and nonliver-related illness, as indicated by their higher biochemical MELD-Na scores, lower platelet count, more frequent diabetes, and greater receipt of mechanical ventilation or hemodialysis at LT. Notably, serum albumin levels were similar among the 3 groups, though this may have been due to receipt of albumin infusions. Additionally, moderate-and high-risk patients had a lower prevalence of HCC. The mean duration of LT surgery was longer for low-risk compared with high-risk patients.
COMPARISON OF POST-LT OUTCOMES BY BRADEN SCALE RISK
Patient outcomes are shown in Table 2 . Patients at high risk for pressure ulcers had the highest mortality, 10.1% during the LT hospitalization and 11.6% within 90 days afterward, which were significantly greater than the low-risk category. Patients at moderate risk for pressure ulcers also had higher in-hospital mortality than the low-risk category (6.8% versus 1.9%; P 5 0.049), but 90-day mortality did not differ. LOS was significantly longer in the moderate (32.4 days) and high-risk (37.4 days) categories compared with low risk (16.2 days). There was no difference among the groups for 30-day readmission rates (range, 27.2%-35.6%; P > 0.05).
We also evaluated post-LT disability, as determined by nonambulatory status at hospital discharge and a requirement for discharge to a rehabilitation facility rather than to home. Significantly fewer low-risk patients (9.9%) were nonambulatory compared with the moderate (27.1%) and high-risk categories (42.0%), and similarly, significantly fewer low-risk NOTE: Data are given as n (%) or mean 6 SD. *P value comparing moderate-risk with low-risk patients. † P value comparing high-risk with low-risk patients. 
UNIVARIABLE ANALYSIS OF POST-LT OUTCOMES
Univariate analyses for the association of Braden Scale category with post-LT outcomes are depicted in We also evaluated the association between MELDNa score and the post-LT outcomes, categorizing patients as MELD-Na < 15, 15-25, or > 25. MELDNa category did not predict post-LT mortality. However, MELD-Na > 25 at LT was associated with prolonged LOS, nonambulatory status at discharge, and discharge to rehabilitation facility. Table 4 depicts our multivariate logistic regression models for ambulatory status at discharge, discharge to a rehabilitation facility, and LOS. Because of an inadequate number of death events during the LT hospitalization or within 90 days to permit multivariate adjustment, we did not evaluate the mortality outcomes. High-risk status was a strong and significant predictor for nonambulatory at discharge (adjusted OR, 4.15; 95% CI, 1.77-9.71), discharge to a rehabilitation facility (adjusted OR, 5.51; 95% CI, 2.57-11.80), and 
MULTIVARIABLE ANALYSIS OF POSTTRANSPLANT OUTCOMES
SUBGROUP ANALYSIS
In order to assess whether Braden score on admission was associated with posttransplant outcomes among those with a long hospitalization prior to LT, we performed a subgroup analysis on patients who underwent transplantation at 7 or more days after admission. A total of 54 patients were identified, with a mean time of 16.8 days between admission and transplantation. Our analysis demonstrated that patients with high-risk Braden Scale scores of less than 16 had significantly longer LOS and greater likelihood of being nonambulatory at discharge or needing discharge to a rehabilitation facility as compared with low-risk patients, which is consistent with our central hypothesis (Supporting Table 1 ).
Discussion
Given the shortage of donor organs relative to patients waiting for LT, it is imperative that organs are allocated to those who would receive the greatest benefit. Although prioritization on the waiting list currently favors patients with the highest expected mortality, the transplant community should also consider the likelihood of patients having good recovery after LT. The concept of frailty extends beyond liver dysfunction and incorporates an assessment of physical activity and overall functional reserve. (2, 8) Certain measures of frailty, such as the Fried Frailty Index, evaluate multiple domains, including balance, strength, and endurance. (9) Therefore, determination of frailty may be a useful tool to predict outcomes after LT, in order to discern which patients may receive maximum benefit from transplantation. On the basis of our analysis, assessment of frailty in LT recipients using a widely available instrument discriminated mortality and disability-related outcomes in the early post-LT period. The strengths of our study included the utilization of a large sample size and the confirmation of a consistent association across 2 different LT centers to account for interhospital and interregional differences in transplantation.
Our study contributes several novel findings. First, we demonstrate that patients at high risk for pressure ulcers had a greater likelihood of being nonambulatory at the time of hospital discharge and were more likely to require a rehabilitation facility after leaving the hospital. High-risk status, in fact, demonstrated a stronger association with disability than all other liver-related and nonliver-related variables measuring illness severity. Second, we found that both moderate and high Braden Scale risk independently predicted longer LOS. Finally, in univariate analysis, high Braden Scale risk predicted higher in-hospital and 90-day mortality after LT. Indeed, prior studies have demonstrated an association between posttransplant mortality and other measures of frailty, such as skeletal muscle index (10) (11) (12) or Karnofsky Performance Status. (13) However, these assessments are not universally performed in all hospitalized patients, and furthermore, skeletal muscle index assessment often requires the use of costly imaging software. As caring for the pretransplant patient is complex and potentially time intensive, the Braden Scale provides a marker for early post-LT outcomes which has the benefit of not requiring additional time or resources, because it is already determined in all patients hospitalized in the United States. In addition, although other measures of frailty have been shown to predict post-LT mortality, our study demonstrates that a high-risk Braden score is associated with both early posttransplant mortality and disability, thus expanding the utility of this tool beyond other frailty assessments. Finally, because the Braden Scale has been demonstrated to have high interrater reliability, (14) our results should be generalizable to other transplant centers.
One clinically important finding from our study is the association between high-risk Braden Scale score and disability after LT, indicated by nonambulatory status and need for discharge to a rehabilitation facility. Given the longer survival after transplantation over the last 1 to 2 decades, increasing attention has deservedly been given to health-related quality of life (HRQoL), which studies have shown can be significantly improved with LT. (15) (16) (17) In particular, overall health perception and quality of life are similar between the general and post-LT populations, except in the domain of physical activity, which is consistently lower in post-LT patients (17) and tends to improve the least after LT compared with other HRQoL domains. (18) Such reductions in HRQoL may also lead to higher rates of depression. (15) Our results suggest that high-risk patients by the Braden Scale assessment may be at increased risk for such adverse HRQoL outcomes, which may subsequently prevent them from having a "new lease on life" after LT.
To address this concern, high-risk LT recipients should be considered for targeted interventions to reduce the likelihood of post-LT disability. One such approach might be engagement in a supervised exercise program early after LT, which may lead to improved physical functioning and ultimately greater HRQoL. (17) At our centers, no specific protocols exist regarding initiation of physical therapy after LT, which is instead left to the discretion of the attending surgeon. Furthermore, participation in physical therapy may be affected by the patient's motivation and beliefs in the benefits of exercise. (19) Therefore, the Braden Scale may identify transplant recipients who should receive a more formal and protocoled exercise program. In a prospective study of solid organ transplant recipients, patients receiving supervised exercise for 3 sessions per week had significantly greater functional capacity and quality of life than a nonintervention control group. (20) Targeting patients with lower Braden Scale scores for a formal exercise program might reduce early post-LT disability and warrants further study.
It is also notable that both high-and moderate-risk patients had prolonged LOS after transplantation, relative to low-risk patients. These results corroborate findings from a prior study in nontransplant patients, which showed that the Braden Scale was an accurate predictor of postoperative outcomes in the geriatric population, with scores <18 predicting longer LOS due to a higher incidence of early postoperative complications. (6) Given the retrospective design of our study, the underlying cause for longer LOS in our cohort could not be ascertained. However, we suggest a future analysis to determine whether prolonged LOS in frail LT recipients is a consequence of surgical complications versus a need for in-hospital rehabilitation, as the latter finding would support prehabilitation as a useful intervention to reduce post-LT LOS.
Our study has several limitations. First, our investigation was retrospective and subject to the biases inherent to this study design. However, we tried to minimize bias by evaluating objectively verifiable variables and outcomes and by adjusting for baseline differences between the groups. Furthermore, the Braden Scale, our primary exposure, had excellent ascertainment and was likely measured consistently in the cohort because it has been uniformly applied by the hospitals' nursing staff since 2008. Second, we limited the number of variables included in our multivariate analyses based on the sample size and number of events to prevent overfitting. We therefore included variables that were most likely to be associated with both Braden Scale and outcomes, but were unable to adjust for differences in donor organ quality. However, we believe that high-risk Braden scale patients would be more likely to receive higher-quality organs, suggesting that the magnitude of our results may be biased toward the null hypothesis because we would expect an even stronger association between high-risk Braden score and post-LT disability, had the analyses permitted adjustment for donor quality. Finally, we were unable to perform multivariate analysis for the mortality outcomes because there were too few death events in our study cohort. Thus, we cannot confirm that greater mortality in the higher-risk Braden Scale categories is independent of confounders, such as severe liver dysfunction or overall illness. A larger, multicenter study would permit the evaluation of the Braden Scale score during the LT hospitalization as a predictor of early post-LT mortality. Because Braden Scale data are already available for all transplanted patients, a study such as this could be performed retrospectively. Alternatively, this relationship could be evaluated at the national level if the United Network for Organ Sharing were to include the Braden Scale score in the Standard Transplant Analysis and Research registry.
In conclusion, our study demonstrates the utility of the Braden Scale, a simple and readily available tool used to assess pressure ulcer risk, as a predictor of early outcomes after LT, particularly those representing disability. The Braden Scale may be a promising tool to prognosticate early post-LT outcomes, and it provides a framework to identify LT recipients likely to require supervised rehabilitation after LT, in order to reduce the risk of post-LT disability and impaired quality of life.
